Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Inventory (2018 - 2025)

Catalyst Pharmaceuticals' Inventory history spans 8 years, with the latest figure at $37.2 million for Q4 2025.

  • For Q4 2025, Inventory rose 90.19% year-over-year to $37.2 million; the TTM value through Dec 2025 reached $37.2 million, up 90.19%, while the annual FY2025 figure was $37.2 million, 90.19% up from the prior year.
  • Inventory reached $37.2 million in Q4 2025 per CPRX's latest filing, up from $28.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $37.2 million in Q4 2025 to a low of $4.4 million in Q1 2021.
  • Average Inventory over 5 years is $14.1 million, with a median of $10.5 million recorded in 2023.
  • Peak YoY movement for Inventory: soared 288.25% in 2021, then fell 13.53% in 2022.
  • A 5-year view of Inventory shows it stood at $7.9 million in 2021, then dropped by 13.53% to $6.8 million in 2022, then soared by 129.89% to $15.6 million in 2023, then grew by 24.91% to $19.5 million in 2024, then surged by 90.19% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Inventory are $37.2 million (Q4 2025), $28.0 million (Q3 2025), and $18.6 million (Q2 2025).